Rexahn Pharmaceuticals Inc Recap

What is your opinion of Rexahn Pharmaceuticals Inc?

Rexahn Pharmaceuticals Inc

AMEX:RNN - Apr. 18th 8:45pm

$ 0.7438 -0.0212 (-2.77%)

Shares of Rexahn Pharmaceuticals Inc – a $133.3 million market cap Biotech company – have fallen -2.77 percent to $0.7438 as of 8:00 PM. With the current share price, Rexahn Pharmaceuticals Inc has a P/E Ratio of 0.00.

Rexahn Pharmaceuticals Inc was incorporated on May 13, 2005 with the merger of Corporate Road Show.Com Inc., a New York corporation ("CPRD"), and Rexahn, Corp, a Maryland corporation, immediately after giving effect to a 1 for 100 reverse stock split and the reincorporation of CPRD as a Delaware corporation under the name "Rexahn Pharmaceuticals, Inc.". The Company is a development stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative treatments for cancer and other medical needs. The Company currently has three clinical stage oncology candidates. The first candidate, Archexin, is an inhibitor of the protein kinase Akt. Akt plays critical roles in cancer cell proliferation, survival, angiogenesis, metastasis, and drug resistance. Another clinical stage candidate is RX-3117, which is a small molecule, new chemical entity nucleoside compound that has an anti-metabolite mechanism of action, and has therapeutic potential in a broad range of cancers, including colon, lung, and pancreatic cancer. Supinoxin, or RX-5902 is another clinical stage oncology candidate that is a first-in-class small molecule that inhibits the phosphorylation of p68 RNA helicase, a protein that plays a key role in cancer growth, progression, and metastasis. The Company's drug candidates would be competing with products and therapies that either currently exist or are expected to be developed. Archexin would compete with other Akt inhibitors, such as MK-2206 and GSK-2141795, which is under development by Merck & Company, Inc. and Glaxo-SmithKline, respectively. It are not currently aware of known inhibitors of phosphorylated p68 that would compete with Supinoxin. The Company holds U.S. patents for Archexin, RX-3117, Supinoxin and RX-0047. It also holds multiple foreign patents for Archexin, RX-3117, Supinoxin and RX-0047. It is regulated by governmental authorities in the United States and in other countries.

Find out more about Rexahn Pharmaceuticals Inc.

Rexahn Pharmaceuticals Inc Stock Price

Rexahn Pharmaceuticals Inc’s (AMEX:RNN) current stock price is $0.7438, down $-0.0212.

Rockville, MD | 1 day ago

Rexahn Pharmaceuticals Inc